J05AR01 • lamivudine + zidovudine • Antiinfectives for systemic use | Direct acting antivirals | Antivirals for treatment of HIV infections, combinations
The combination of lamivudine and zidovudine is used for the treatment of HIV-1 infection. Both substances are antiretrovirals that inhibit viral replication by interfering with reverse transcriptase.
The medication is taken orally, usually twice daily, as directed by a doctor. It is important to follow the treatment regimen to prevent the development of viral resistance.
Side effects may include nausea, anemia, fatigue, or muscle pain. In rare cases, lactic acidosis, myelosuppression, or severe allergic reactions may occur.
This combination is not recommended for patients with severe renal impairment, severe anemia, or hypersensitivity to any of the components.
Substance: lamivudine + zidovudine
Date of last drug list: 01-03-2024
Commercial code: W69954005
Concentration: 150mg / 300mg
Pharmaceutical form: tablets
Quantity: 60
Product type: generic
Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).
Manufacturer: MC DERMOTT LABORATORIES LTD. TRADING AS GERARD LAB - IRLANDA
Holder: VIATRIS LIMITED - IRLANDA
Number: 10644/2018/06
Shelf life: 4 years-after packing for marketing; after the first opening of the bottle-60zile